FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
About
ceo
Dr. Laurence A. Turka M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.rubiustx.comexchange
NASDAQ
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
CIK
0001709401
ISIN
US78116T1034
CUSIP
78116T103
Address
399 Binney Street
Phone
617 679 9600
Country
US
Employee
6
IPO Date
Jul 18, 2018
Key Executives
Name
Title
Pay
Year Born
Mr. Craig R. Jalbert CIRA
President, Treasurer, CS, Principal Exe ...
0
1962
Ms. Dannielle Appelhans
Chief Executive Officer & Pres
422.98k
1983
Mr. Jose I. Carmona M.B.A.
Principal Accounting Officer & Treasurer
659.2k
1972
Ms. Marissa Hanify
Director of Corporate Communications
0
N/A
Dr. Laurence A. Turka M.D.
Chief Scientific Officer and Head of Res...
626.55k
1958
As of December 31, 2024, the total employee count stands at 6, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
